Last reviewed · How we verify
NCT04100187
Immunotherapy With CD19 CAR T-cells for B-Cell Leukemia
Phase 1 trial testing Anti-CD19-CAR in Leukemia in 100 participants. Status unknown.
1 August 2023
Quick facts
| Lead sponsor | Kecellitics Biotech Company Ltd |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 1 February 2023 |
| Primary completion | 1 August 2023 |
| Estimated completion | 1 August 2024 |
Drugs / interventions tested
- Anti-CD19-CAR
Conditions studied
- Leukemia — all drugs for Leukemia →
Sponsor
Kecellitics Biotech Company Ltd — full company profile →
Who can join
Adults 2 to 70, any sex, with Leukemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to evaluate the safety, efficacy and duration of response of CD19 Chimeric Antigen Receptor (CAR) redirected autologous T-cells in patients with high risk, relapsed CD19+ haematological malignancies.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant.
Cao XY, Zhang JP, Zhao YL, Xiong M, et al · · 2023 · cited 11× · PMID 37469510 · DOI 10.3389/fimmu.2023.1191382
Verify or expand the search:
- PubMed search for NCT04100187
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Anti-CD19-CAR
Trials testing the same drug.
- NCT02546739 — Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL · Phase 1 · unknown
Other recruiting trials for Leukemia
Currently open trials in the same condition.
- NCT07405424 — Spiritual Care Intervention in Adult Patients Diagnosed With Acute Leukemia · NA · recruiting
- NCT07249346 — Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease ( · Phase 2 · recruiting
- NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
- NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
- NCT07148180 — A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: · Phase 1, PHASE2 · recruiting
Other Kecellitics Biotech Company Ltd trials
Trials by the same sponsor.
- NCT05651100 — Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma · Phase 1, PHASE2 · unknown
- NCT04163575 — Immunotherapy With CD22 CAR T-cells for B-Cell Lymphoma, ALL and CLL · Phase 1, PHASE2 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04100187 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kecellitics Biotech Company Ltd
- Last refreshed: 1 December 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04100187.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing